Emerging Targeted Therapies and Evolving Treatment Paradigms in Non-Small Cell Lung Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 8
Special Issue Editor
Special Issue Information
Dear Colleagues,
During 2024 and 2025 several new targeted therapies have been FDA approved for NSCLC and several more are coming in 2026. In this special issue we want to review not only the latest approvals in targeted therapy but also some of the agents that are not as popular or well know as others. For example Her2 therapy or MET amplification therapy in lung cancer have had a major boost in the last two years with the approvals or zongertinib or Telisotuzumab vedotin and more agents are coming in these fields. We will review mechanisms of action, efficacy and toxicity management of several of these new agents. Also current indications and near future potential indications in the management of NSCLC.
Dr. Luis E. Raez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer (NSCLC)
- targeted therapies
- human epidermal growth factor receptor 2 (HER2)
- mesenchymal-epithelial transition factor (MET)
- anaplastic lymphoma kinase (ALK)
- C-ROS oncogene 1 receptor tyrosine kinase (ROS1)
- rearranged during transfection (RET)
- neurotrophic tyrosine receptor kinase (NTRK)
- B-Raf proto-oncogene serine/threonine kinase V600 mutation (BRAFv600)
- Kirsten rat sarcoma viral oncogene homolog (KRAS)
- epidermal growth factor receptor (EGFR)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
